Right Rebate Act of 2019
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jan 31, 2019)
Right Rebate Act of 2019
This bill requires drug manufacturers with Medicaid rebate agreements for covered outpatient drugs to disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).
What just happenedJan 31, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Who’s behind it
- Introduced in HouseJan 31, 2019
- Jan 31, 2019IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Jan 31, 2019IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Jan 31, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jan 31, 2019IntroReferralIntro-H
Introduced in House
- Jan 31, 2019IntroReferral1000
Introduced in House